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1 
EXPLANATORY  MEMORANDUM  AND  REPORT  TO  THE  COUNCIL 
on  the  transpa~~ncy  of  measures  regulating  the  pricing  of  medir.inal 
products  for  human  use  and  their  inclusion  within  the  scope  of  the  h•alth 
insurance  system  and  on  future  Community  activities  in this field 
I.  G::tiERAL  CONSIDERATIONS 
1.  The  nature of  national  controls 
Within  the  Comm•mity,  only  about  20%  of  medicinal  products,  in 
terms  of  value,  are  directly  purchased  by  the  consumer.  The 
remainder  are  prescribed  b)'  a  physician  and  the  whole  or  part  of 
the  cost  is  met  by  the  public  authorities  through  the  national 
health  ins~rance system.  Expenditure  on  pharm~ceuticals represents 
between  10%  and  20%  of national  health  care expenditures.  In  these 
circumstances,  all  the  Member  States  have  adopted  measures  to 
control  public  expenditures  on  pharmaceuticals,  and  in  recent 
years, 
security 
io~ith  the  ons~t  of  the  crisis  within  the  national  social 
systems,  the  general  trend  has  been  towards  the 
intensification of  controls.  However,  the nature and  severity of 
the controls differs considerably  between  the Member  States. 
In  five  Member  States,  Belgium,  Greece,  Spain,  Italy and  Portugal, 
a  new  medicinal  product  can  only  be  marketed  after  the  national 
authorities have  agreed  the  p~ice of the product.  In  these  Member 
States and  in  France,  strict controls are exercised on  the  range  of 
products  covered  by  the health insurance  system,  and  ih general,  a 
new  product  will  not  be  admitted  to  the  list  of  products  eligible 
for  reir.1bursement  unless  the  authorities  are  satisfied  that  it -2-
offers  a  significant  ·financial  or  therapeutic  advantage  over 
existing  therapies.·  Moreover,  in several  of  these  countries the 
price of  medicinal  products  already on  the market  has  been  subject 
to freezes  and  the  increases allowed  have  been  less than  the  level 
of  inflation. 
In  the  United  Kingdom,  although  manufacturers  are generally free  to 
set  prices  for  individual  products,  the  overall  profits  made  by 
firms  in  their  dealings  with  the  national  health  service  are 
controlled.  The  authorities  have  recently  introduced a  system  of 
11selected  lists
11  which  allows  for  the  exclusion  from  the  health 
insurance  system  of  more  expensive  products  falling  within  seven 
therapeutic  groups,  if cheaper  alternatives are available. 
In  the  Netherlands,  the  price of  new  medicines  is not  controlled, 
although  price increases are.  Moreover,  as  in  the  case of  Denmark, 
provision  is  made  for  the  exclusion  of  more  expensive  medicines 
from  the  scope  of  the  health  insurance  system  if  cheaper 
alternatives are available. 
In  Germany,  the price of  medicines  is uncontrolled,  and  there is no 
possibility of  excluding  products  from  the health  insurance  system 
on  the  grounds  that  cheaper  alternatives  are available.  However, 
in  order  to  make  financial  savings,  a  number  of  therapeutic 
categories have  been  entirely  excluded  from  coverage  by  the  health 
insurance  system. 
Ireland  and  Luxembourg  are  largely  dependant  on  medicines  imported 
from  neighbouring  countries  and  prices  are  fixed  by  reference  to 
the  prices  prevailing  in  those  countries,  plus  an  appropriate 
margin  to cover  the  costs of  importation. .· . 
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It should  be  noted  that,  even  ·in  tho~e Member  St~te~•  wh~re prices 
are  not  directly  controlled,  pharmaceutical  companies  will  be 
subjer.t  to  supervision  by  the  national  and  Community  competition 
authorit·ies.  Moreover,  several  Member  States  have  attempted  to 
sensitize  doctors  to  the  cost  of  the  medicines  they  prescribe  by 
transparency  lists or  national  formularies,  and  in  some  countries 
there  is  a  system  of  direct  r,\Onitoring  of  doctors  prescribing 
habits. 
2.  Their effect on  the  common  market 
The  disparities  which  exist  in  the  national· systems  of  price  and 
social  security  reimbursement  controls  clearly  affect 
intra-Community  trade  in  medicinal  products.  In  f~ct ~  survey  of 
pharm~ceutical prices  carri~d out  by  the  Statistical Office  of  the 
european  ·Communities  in  1983  found  the  existence  of  wide 
differentials  in  the  prices  of  pharmaceuticals  between  the  Member 
States  (TABLE  1), and  this has  been  confirmed  by  two  recent  studies 
carried  out  for  th<e  Commission  b)'  the  Economists  Advisory  Group 1 
and  the European  Bureau  of  Consumer  Unions2•  Moreover,  the  recent 
increase in  the volume  of  parallel  importing  of  medicinal  products 
into  certain  Member  States  itself  provides  empirical  evidence  of 
the  existence  of  wide  price differentials  for  individual  products 
within  the  Community.  On  various  occasions,  the  European 
Parliament,  certain Member  States, the pharmaceutical  industry and 
consumer  groups  have  all criticised the  vari~tions in the  prices of 
medicinal  products  which  exist  and  the  distorting effect  which  they 
have  on  intra-Community  trade, albeit  from  different  perspectives. 
1  The  C:ommunity •s  Pharrnaceuti cal  Industry,  1985 
2  The  Consumer  and  Pharmaceuticals  in the  E.E.C.,  1984 -4-
Decisions  to exclude  products  from  the  scope  of  the national  health 
insurance  system  also  effect  intra-Community  trade,  since,  in 
practical terms,  a  decision to exclude  a  prescription only drug  in 
this  way  may  be  tantamount  to  its  exclusion  from  the  national 
market. 
3.  The  industrial policy dimension 
Hitherto,  the European  pharmaceutical  industry  has  enjoyed  a  strong 
competitive  position  on  world  markets  and  its record  of  innovation 
has  been  good.  Recent  scientific developments,  in  particular  in 
the  field of  biotechnology,  hold  out  the  prospect  of  entirely  new 
perspectives  for  pharmaceutical  research  with  the  possibility  of 
offering  effective  treatments  for  hftherto incurable  diseases,  of 
offering  better  treatments  for  existing  diseases  with  fewer  side 
effects,  or  of  replacing  surgical  intervention  by  drug  therapy. 
However, 
costlier. 
pharmaceutical  research  is  also  becoming  long~r  and 
At  the  present  time  it  takes 8  - 10  years  to  develop  a 
major  innovatory  product  and  complete  all  the  tests  and  trials 
required,  at  a  total  cost of 50- 100  million  ECUs.  This  research 
and  development  expenditure  is  primarily  financed  by  the  industry 
itself, which  devotes  10-15%  of  its turnover  to it. 
This  phenomenon  presents  the  national  authorities  with  a  dilemma 
since  it  is  clear  that  the  single-minded  pursuit  of  short-term 
financial  economies  will  effectively  undermine  the  research 
capacity  of  the  pharmaceutical  industry.  At  the  present  time, 
therefore,  each  Member  State  must  balance  the  objective  of 
controlling  public  expenditures  on  pharmaceuticals  against  the 
objective  of  maintaining  a  competitive  research-based 
pharmaceutical  industry.  Hitherto,  the  reconcilation of  these  two 
policy  objectives  has  taken  place  at  national  level.  Some 
cou~tries,  with  a  well-established  domestic  pharmaceutical 
industry,  have  adopted  policies which  are broadly  favourable  to  the 
development  of  pharmaceutical  research.  Other  countries, 
particularly  those  who  are  more  dependant  on  pharmaceutical 
• 
" ., 
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imports,  have  tend~d to  give  8  higher  priority  to  the  need  for 
savings~  However,  ·  in  recent  years,  some  of  the  countries  with 
strict price  control  systems  have  recognised  the need  to  encourage 
pharmaceutical  research,  and  a  variety  of  schemes  have  been 
developed  for  this  purpose.  !nevi tably,  such  schemes  have  been 
developed  by  referencoe  to  national  perspectives  and  they  are  not 
~lways easy to  r~concile with  the  fundamental  principles of  the  EEC 
Treaty  relating  to  the  free  movement  of  goods  or  to  fair 
competition.  There  is  therefore  an  urgent  ne~d  fot  a  Community 
strat~gy  which  will  reconcile.  the  need  to  ensure  that  reasonable 
prir.es  are  paid  for · meclication  with·  the  need  to  encourage  the 
development  of  a  research-based pharmaceutical  industry  in Europe. 
4.  Other disparities  in the market  for  pharmaceuticals 
The  ex1stence of national  systems  of  controls on  the  prices  charged 
by  the  manufact•Jrers  of  medicinal  products  and  of  limitations  on 
ti'le  range  of  medicinal  products  covered  by  the  health  insurance 
system  is  undoubtedly  a  major  causP.  of  the  price  differentials 
whith  currently exist.  However,  other factors  are also  important. 
At  the  present  time  the  market  for  pharm3ceuticals  within  the 
Community  is  characterised  by  a  remark.abl~  degree  of  diversity. 
Like  prices,  levels  of  pharmaceutical  consumption  also  differ 
considerably  between  the  Member  States  (TABLE  I>.  Germany,  with 
~rguably the highest  prices in the  Community,  also has  the highest 
c~ms•Jmptioi"'  rate,  at  $  U.S.  90  per  capita.  However,  three 
countrie~ with  low  prices  also have  high  consumption  rates  in money 
terms,  France  <$  u.s.  80  per  capita>,  Belgium  <$  67  per  capita>  and 
Italy<$  56  per  capita>.  In  contrast,  three  countries  with 
comparatively  high  prices  have  relatively  Low  consumptiori  rates  in 
money  terms,  Netherlands  <$  35  per  capita>,  Denmark  <$  38  per 
capite;)· and  the  U11ited  Kingdom  <$  51  per  capita>.  These  figures 
suggest  the  existence of  considerable variations  of  consumption  in 
volume  terms. 3 
4 
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Similar  differences  are  reflected  in  the  statistics available  for 
consumption  by  therapeutic  group.  Thus,  in  money  terms,  the 
systemic  antibiotics  accounted  for  20X  of  Greek  pharmaceutical 
consumption,  but  only  3X  of  German  pharmaceutical  consumption  in 
1982.  Medicines  affecting  the  central  nervous  system,  including 
analgesics  and  psycholeptics,  took  7X  of  the market  in Italy,  and 
22%  of  the  Danish  market3• 
It  would  be  difficult,  if  not  impossible,  to  know  how  these 
differences  in  consumption  rates  would  affect  price  formation  in 
the  absence  of  controls.  However,  it  does  seem  reasonable  to 
presume  that  such  differences  will  be  reflected  in  the  prices 
Member  States  allow  to  be  charged  for  medicinal  products,  and  in 
particular  how  an  allowance  for  research  and  development  costs  is 
to be  reflected  in  the price of  a  specific product. 
Another  factor  which  is  important  when  considering  differences  in 
the  resale  price  of  medicinal  products  between  the  Member  States 
are  the  differences  in  taxes,  and  in  the  margins  allowed  for 
wholesalers  and  retail pharmacists.  Thus  in  1984,  the  retail price 
of  a  medicinal  product  with  an  ex-factory  price  of  10  D.M.  would 
have  varied between  16.10  D.M.  in Italy and  22.10  D.M.  in  Denmark. 
The  effect  of  such  differences  on  intra-Community  trade  is, 
however,  much  less, and  the Commission  does  not  envisage presenting 
proposals  on  the  manner  in which  pharmacists  are  remunerated  in the 
different  Member  States. 
5.  Th~ object~~s of  Community  legislation 
Following  the  adoption  of  five  substantive  directives4, 
considerable  progress  h~s  been  made  towards  the  elimination  of 
Economist3  Advisory  Group,  The  Community's  Pharmaceutical  Industry,  1985 
Council  Directive 65/65/EEC,  O.J.  No.  22,  9.2.65,  p.  369/65 
Council  Directive  75/318/EEC,  O.J.  L 147,  9.6.75,  p.  1 
Council  Directive  75/319/EEC,  O.J.  L 147,  9.6.75,  p.  11 
Council  Directive 78/25/EEC,  O.J.  L 11, 14.1.78,  p.  18 
Council  Directive 83/570/EEC,  O.J.  L 332,  28.11.83,  p.  1 -7-
barriers to trade  resulting from  national  public  health  l~gislation 
designed  to  en5ure  the  qualit)·,  safety  and  efficacy  of  medicinal 
products.  In  accordcmce  wi-th  the  White  Paper  on  the  Internal 
Mark~t, proposals  to  elimin~te the  remaining  barriers to  trade will 
~e presented  by  1989.  As  the free  movement  of  med1cinal  products 
b€·co111es  easier,  the  effc!:ts  of  national  price  controls  are  no 
Lenger  confined to the  Member  State  in question.  In  recent  years  a 
significant  parallel  trade  in  pharmaceutical  products  has 
developed,  with  products  purchased  in  the  lower  price  countries 
bein~  imported  into ·the  higher  price  countries  and  sold  there, 
sometimes  at substantial discounts. 
The  fundamental  aims  of  Community  ~egir.lation on  price controls and 
the  social  security  reimbursement  of  pharmaceuticals  should  be 
two-fold. 
Th~ ti rst  aim  mtJst  be  to  ensure  that  the  measures  taken  by  Men1ber 
States to control  pharmaceutical  expenditures do  not  pose  a  barrier 
.to the  creation of  a  genuine  internal market  for  the  pharmaceutical 
sector by  1992.  However,  the  realisation of  the  internal market  is 
not  an  end  in  itself  but  the  means  to  the  creation  of  a  more 
favourable  environment  for  stimulating enterprise,  competition and 
~rade.  As  the  White  Paper  "completing  the  Internal  Market"  points 
out, the  Commission's  approach 
"< ••• > must  aim  not  simply  to  remove  technical  barriers  to 
··trade,  but  to  do  so  in  a  mann~r  which  will  contribute  to 
increasing  industr~al efficiency and  competitiveness,  leading 
to greater wealth  and  job creationM  (paragraph  62). 
Secondly  the  Commission  considers· it  i_mportant  to  ensure  that 
Community  activity  in  this  sector  takes  account  of  the  specific 
ne~d  to  encourage  the  future  development  of  the  innovatory 
phar~aceutical  industry,  while  making  appropriate  provision  to 
ensur.e  that  the  industry  does  not  make  excessive  prcfits  in  its 
dealings  ~ith the national  health  services.  This  is not  merely  an -8-
economic  objective.  The  maintenance  of  a  trigh  level  of  public 
health  within  the  Community  will  to  a  large  extent  depend  on  the 
activities of  the  Community's  own  pharmaceutical  industry.  It will 
not  be  in  the  intP.rests of  the  European  patient to become  dependant 
on  research  conducted  in third countries. 
In  addition,  any  Community  legislation  should  also  contribute 
towards  the  realisation  of  the  other  objectives  of  the  Treaty  in 
the  pharmaceutical  sector,  in  particular  the  full  application  of 
the  Treaty  rules  on  competition within  the  common  market  <in 
particular Article 5  in  connection  with  Articles 85  and  86).  It must 
also take properly  into account  the  needs  of  the  Member  States  in 
ensuring  the availability of  an  adequate  supply  of  medicines at a 
reasonable  cost  for  their citizens. 
6.  A progressive approach 
Preceding  sections of this note  have  shown  that  at  the  present  time 
there  is  no  consensus  on  the  proper  role  of  the  public authorities 
in  regulating pharmaceutical  pricing and  reimbursement.  In certain 
Member  States,  very  interventionist  techniques are  used  and  state 
regulation  has  substituted itself for  competitive forces.  In other 
Member  States,  greater  reliance  has  been  placed on  the effects  of 
competition  in  restraining  price  increases.  The  Commission 
considers  it  would  be  premature  at  present  to  propose  the  full 
scale  harmonisation  of  national  price  control  and  health  insurance 
measures.  Instead,  the  Commission  envisages  a  progressive approach 
to the  problem. 
In  the  first  instance,  it  is  considered  necessary  to  ensure  that 
the  fundamental  principles of  the  EEC  Treaty  are  fully  respected in 
the  operation  of  national  price  control  and  health  insurance 
sys~ems.  In  its  recent  Communication  on  the  compatibility  with 
Article  30  of  the  EEC  Treaty  of  measures  taken  by  Member  States 
relating to  price controls and  reimbursement  of medicinal  products, 
the  Commission  has  explained  the  conclusions  which  it  has  drawn -9-
from  the  rel~vant  juri~prud~nce of the  Court  of  Justice.  However, 
~t  appears  desirable  to  supplement  this  jurispru~ence with  certain 
rules· cf  positiv~  law  designed  to  ensure  that  national  price 
control  ~nd reimbursement  systems  cp~rate in a  fair and  tr~nsparent 
m~nncr.  The  Commissic•n  has  therefore  adopted  a  pr:>pos,;;~l  for  a 
Council  r,irective  rel.ating  to  the  transpilrem~y  ;;.f  :r.easures 
rcgulilting  the  pricing  of  m~dicinal  products  fct·  h!Ji!lan  vse  and 
their  inclusion  within  the  scope  of  the  hec:lth  insur~nce system. 
Thf!  obj£ctives  aod  r.ontent  of  this  proposal  a;~  ck"r.ribeci  in 
Section II. 
In  addition,  the  Commission  coi"isiders  that  it  is  necessary  to 
consider  the partial  approxim~tion of national  measurez  in  ord~r to 
orientate  the~  tow~rds systems  ~hich have  a  less  disruptiv~ effect 
on  the  operation  of  the  common  ll'it:~rket  and  t;,~ke  into  accotmt  the 
legitim~te  industrial ·pol  icy  objectives  of  the  Comr.nmHy  as  a 
whole.  The  Commission  intends  to engage  in  a  round  of  intensive 
ccnsultations  with .interested parties in order to better define the 
m~thoris by  which  th~se objectives  P.light  b~  ar.hieved.  As  ~  basis 
for  c.lisct~ssion,  and  without  in  any  ~o~ay  prejudicing  any  )'IJture 
p~·opo!Sals  which  it  might  make,  the  Commission  has  t~ken  this 
opportunity  to set  out  several  initial  reflections on  this matter 
in Section :UL 
II~  THE  PROPOSAL  FOR  A TRANSPARENtY  DIRECTIVE 
If·  the  Community's  pharmaceutical  industry  is  to  remain 
com9et1ti'Je,  it must  be  protected  from  discrimination  within  its 
o~n internal  mar~et.  The  Cnmmission's  experience  in  investigating 
compl<lints  that  national  measures  infringf:  the  free  movement  of 
~oods  rules  of  the  Tr~aty  suggests  that  there  is  a  lack  of 
tr~nsparen~y  in  the  manner  in  which  the  national  systems  are 
applied.  Th~ ·  ~'n'~?:.>  of  the  game"  are not  clearly defined  so  that -10-
it is difficult  to  foresee  how  a  given  product  will be  treated, and 
even  after a  decision  has  been  taken,  manufacturers  are not  always 
sure  of  the  real  reasons  for  that  decision.  Moreover  consumer 
groups  and  Members  of  the  European  Parliament  have  criticised  the 
absence  of  transparency  within  the  pharmaceutical  sector. 
The  basic objective of  the proposal  for  a  directive is therefore to 
enable  all  concerned  to  verify  that  the  requirements  of  Community 
law  are  being  respected  by  Laying  down  a  series  of  rules  relating 
to time-limits,  the  reasoning  and  publication of  decisions,  etc., 
which  would  be  directly  effective  so  that  those  concerned  can 
defend  their  interests  before  the  national  courts.  In  addition, 
the  proposal  provides  for  cooperation  at  Community  level.  The 
correct  implementation  of  these  provisions  will  make  it  easier  to 
detect  abuses,  whether  on  the  part  of  industry  or  the  Member 
States,  and  will  therefore  make  a  limited  although  significant 
contribution  towards  improving  the  operation  of  the  Common  Market 
in  this  sector. 
In  two  important  cases5,  the  Court  of  Justice  has  provided 
guidance  on  the  application  of  Articles  30-36 of  the  EEC  Treaty  to 
national  price  control  and  reimbursement  measures  affecting 
medicinal  products.  The  Commission  has  explained  the  conclusions 
it  has  drawn  from  this  jurisprudence  and  has  explained  the  policy 
it  will  adopt  towards  alLegations  of  infringements  in  the 
Communication  referred to above.  It is  important  to emphasise  that 
the  present  proposal  is  intended  to  complement  this  body  of 
pre-existing  law.  It  is  not  intended  to,  and  indeed  cannot 
derogate  from  these  fundamental  principles.  In  presenting  this 
proposal,  the  Commission  reserves  the  right  to  commence  proceedings 
under  Article  169  of  the  EEC  Treaty  or  to  pursu~  such  proceedings 
as  have  already  been  opened  against  Member  States which  in its view 
have  faile~ to  fulfil  the  obligations  incumbent  upon  them  in  this 
sector  under  the  EEC  Treaty. 
5 Case  181/82  Roussel  119837  ECR  3849. 
Case  238/82  Duphar  £198~7 ECR  523. -11-
A  proposal  to  increase  the  transparency  of  national  procedures 
relating  to  price  control  and  reimbursement  of  medicinal  products 
must  necessarily  rel.ate  primarily  to  the  obligations  of  Member 
States during  the decision-making  procedure.  However,  it  should 
not  be  thought  that  all  the  obligations  lie  on  the  one  side only. 
If any  system  of  price  or  reimbursement  controls  is  to  operate 
fairly,  it  is  incumbent  upon  the  manufacturer  to  provide  such 
information as the authorities  may  reasonably  request  and  to engage 
in  an  open  dialogue  in  which  each  side  takes  account  of  the needs 
of  the  other.  Thus  the  proposal  requires  manufacturers  to  give 
re~sons  fo~ the  prices  they  wish  to charge. 
2.  Price cont;ols  on  individual  medicinal  products 
In  countries  where  the  marketing  of  a  new  medicinal  product  is 
permitted  only  after  the  competent  .national  authorities  have 
approved  the  price  for  that·  product,  the  following  rules  would 
apply.  The  manufacturer  would  be  obliged to notify  the authorities 
of  his  intention  to  market  a  medicinal  product,  indicating  the 
price  at  which  he  ·proposed  the  product  be  sold  and  providing 
appropriate  information  in support  of  his proposal.  The  competent 
authorities concerned  would  be  required  to  reach  a  decision on  this 
notification within 90  days  of  its receipt.  Should  the authorities 
reject  the  price  proposed  by  the  firm,  they  would  be  obliged  to 
give  a  detailed  statement  of  reasons.  There  would  be  a  right  of 
appeal.  Analogous  provisions  would  apply  in  c·:ountries  where  the 
price of medicinal  products  can  be  increased only  with  the approval 
of the authorities. 
3.  Frice freezes 
Long  term  price  freezes  can  have  a  particularly  disruptive  effect 
on  the  operation  of  the  common  market,  because  they  prevent 
differences  in  relative inflation rates and  currency  movements  from 
being  reflected  in  the  price  of  products.  The  Commission  is 
therefore  proposing  that  in  the  event  of  a  general  freeze  on -12-
pharmaceutical  prices,  the  Member  State  concerned  should  be 
required  to  review  and  if  necessary  adjust  the  overall  level  of 
pharmaceutical  prices  at  least  once  a  year,  or  whenever  the 
national  resale  price  index  has  increased  by  10%  since  the  last 
review.  In  addition,  any  firm  should  be  able  to  submit  an 
application  for  a  derogation  from  the .freeze  and  be  entitled  to a 
decision  from  the competent  authorities within  90  days~ 
In  reviewing  prices,  Member  States will  wish  to take a  wide  variety 
of  factors  into account,  including not  only  the economic  indicators 
referred  to  above  but  also  such  factors  as  changes  in  the  market· 
situation and  the  gains  in  efficiency which  might  be  expected. 
4.  Profit .controls 
When  a  Member  State  resorts  to  a  system  of  controls  on  the 
profitability of pharmaceutical  firms,  it does  not  specify a  single 
target  rate  of  profit  which  is  applicable  to  all  companies 
operating  within  the  sector.  The  rate  of  profit  allowed  is 
variable,  with  somewhat  higher  profits being  given  to  firms  which 
engage  in  successful  pharmaceutical  research  or  which  increase 
their efficiency.  Thus  the  target  rate of  profit for  each  firm  is 
fixed  individually.  Since  the  rate will  depend  on  such  factors  as 
the  investment  programme  of  the  firm, 
development  activities,  there  is  a  strong 
suggests  that  individual  profit  rates 
and  its  research  and 
body  of  opinion  which 
must  be  confidential. 
Nevertheless,  the  Commission  considers  that  it  is  incumbent  on 
Member  States  who  operate  such  a  system  to  publish  certain 
information  each  year  so  that  each  company  can  verify  that  it  is 
being  fairly  treated.  This  information should  include the average 
target profit  for  the  industry as  a  whole  for  the year  in question, 
and  the  minimum  and  maximum  rates,  and  the  criteria  used  in 
deciding on  the target  rate for  each  firm. -13-
5.  Social  Security  Rei~bursement 
As  noted  above,  in  certain Member  States a  medicinal  product  will 
not  be  available under  the national  health  insurance  system  unless 
"it  has  been  included  in  a  positive  list,  while  in  other  Member 
States  negative  lists  of  products  exc luced  from  the  scope  of  the 
~ational health  insurance  syste~ are used. 
Where  a  system of positive  lists is used,  the  Member  Stc.tes  shoul(j 
er"sure  that  decisions  are  reached  on  appl"! ,.:ztions  ~ithin  90  days. 
1\s  the  Com!!lission  has  stated  in  th'!  Communicatio1·,,  deCisions  to 
exdude  products  from  reimbursement  l'l'ttSt  be  ve;ifiable  by  every 
irr;porter.  This  means  that  reasons  must  be  given  for  national 
decisions.  "t-:~hen  the  reason  given · for  exclusion  relates  to  the 
existence  on  the  market  of  other  products  having  ,~n  eqtJivalent 
t:1erapeuti c  effect,  the  decision  must  name  these  prorlucts,  give 
the.i.r  prices  and  details  of  the  dosage  and  duration  of  treatment 
us~d to compare  prices."  Moreover,  decisions  "must  be  notified to 
the  firms  concerned  with  an  indication  ~f the. means  ~f  r~dress open 
against  such  decisions  and  the  time-limits  ~ithin  which>  appeals 
must  be  made
11
•.  Analogous  provisions are  l:!id down  for  a  system  of 
negative  lists. 
6.  C  lassi  fi cat  ion of  products. eligible for  r'!·i m~~~~!!!.~. 
The  classification  of  medicinal  products  presents  particular 
d-ifficulties,  and  several  international  classifications  are 
availi'ible.  Nevertheless,  within  the  framework  of  reimbursement, 
classification  is  particularly  important  because  it  affects  the 
choice  of  the  reference  products  which  are  used  to  decide  whether 
or not  a  new  product  represe~ts value  for  money.  Moreover,  in  some 
Member  States,  ~ifferences  i~  classification  may  affect  the -14-
proportion of  the  cost  of  the  medicine  which  is  reimbursed  to  the 
patient.·  The  proposal  therefore  envisages  delegating  to  the 
Commission,  after consulting a  Consultative  Committee,  the  power  to 
issue  a  directive  to  harmonise  the  classification  of  medicinal 
products  for  social security purposes  within  the  Community~ 
7.  "Transfer prices" 
For  well  known  economic  reasons,  the  pharmaceutical  industry  is 
organised  on  a  multi-national  basis.  Research  and  development 
activities  and  the  manufacture  of  active  prin~iples  is  often 
concentrated at  a  limited number  of  sites, and  the  active principle 
or  an  intermediate  product  is  taken  to  the  importing  country  for 
the  manufacture  of  the  final  product.  In  fact  trade  in 
intermediate products  is of  considerable  economic  significance  and 
much  of it consists of transfers within  the  same  group  of  companies 
rather  than  "arms-length" transactions.  In  any  system  of  price or 
profit controls,  the  competent  authorities  have  the difficult task 
of  verifying  the  reasonableness  of  these so-called transfer prices. 
The  Commission  considers  that  this.  is  a  matter  for  further 
consideration  at  Community  level.  The  Commission  is  therefore 
proposing  that  those  Member  States  which  do  attempt  to  verify 
transfer  prices  should  be  required  to  notify  the  criteria  used  to 
the  Commission,  and  provision is made  for  the  future approximation 
of these criteria, if necessary. -15-
III.  THE  FUTURE 
1.  General 
There· are  those  who  question  the  need  for  any  form  of  control  on 
pharmaceutical  pricing  or  the  reimbursement  of  medicinal  products 
and  accordingly  argue  that  price  formation  in  the  pharmaceutical 
sector should  be  left to market  forces.  This  point  of  view  appears 
unrealistic.  For  as  long  as  the  public  authorities  meet  a 
substantial  part  of  the  cost  of  medicinal  products  through  the 
national  health  insurance  system,  the  competent  authorities  will 
have  a  legitimate interest  in ensuring that  good  value for  money  is 
obtained  and  in  ensuring  that  companies  do  not  make  excessive 
profits.  As  mentioned  above,  in addition to providing support  for 
the  Member  States,  the  aims  of  Community  policy  must  be  to ensure 
that  such  measures  do  not  adversely  affect  the  operation  of  the 
internal  market  and  take due  account  of  the  need  to maintain  a  high 
level of  innovation within the  Community. 
2.  Prices  of  products  which  are  not  avai table  under  the  national 
health -insurance  system 
The  primary  justification  for  imposing  controls  on  pharmaceutical 
prices  is  the  need  to  control  expenditures  in  the  national  health 
insurance system.  This  justification does  not  apply in the  case of 
products  which  are not  available under  the health  insurance  system. 
In  the  case  of  products  which  can  be  purchased  directly  by  the 
consumer,  normal  competitive prices apply,  since  the  consumer  can 
select  the  product  which  represents  the  best  value  for  money 
~imself,  if  necessary after  consulting  the  pharmacist.  It  would 
therefore  seem  appropriate  to  aim  for  the  elimination  of  controls 
on  these  products,  although  Member  States  would  still  be  able  to 
impose  a  freeze  on  their prices,  provided that  such  a  freeze  also 
applied  t:  c:ther  sectors  of  the  economy  as  part  of  an  overall 
anti-inflation strategy. -16-
3.  Price and  profit  controls 
In  general  terms,  it  is  possible  to  distinguish  between  three 
systems  of  controls  which  are  used  within  the  Community  at  the 
present  time:  price control  based  upon  costs;  price control  based 
upon  a  comparaison  with  other  products  and  profit  control.  All 
three  systems  have  their  disadvantages.  In  a  system  of  price 
control  based  upon  the  actual  costs  incurred  by  the  product  it  is 
difficult  to  obtain  the  information  necessary  to  calculate  the 
overall price.  Moreover  a  cost  plus price control  system  contains 
no  incentive  for  firms  to  increase efficiency  in production  if all 
the  costs  actua~~y incurred are  taken  into account.  In  a  system  of 
price  control  based  upon  a  comparaison  between  products,  the  choice 
of  reference  products  may  be  difficult  and  controversial, 
particularly  in the  case of  a  major  innovatory  product  where  there 
is  no  obvious  substitute.  Moreover  any  system  of  individual 
product  price  controls  reduces  whatever  possibilities  for  price 
competition exist  within  the  pharmaceutical  sector.  On  the  other 
hand,  while  a  system  of  profit  control  does  leave  some  scope  for 
competitive forces,  its administration is  complex,  and  it needs  to 
be  carefully  adjusted  if  it  is  to  achieve  the  objectives  of 
promoting  innovation  and  efficiency  while  maintaining  reasonable 
prices. 
In  these  circumstances,  the  Commission  does  not  consider  it 
possible to  hold  up  one  or other system  as  a  model  for  those ·Member 
States  who  wish  to  operate  a  price  control  system.  Instead,  the 
Commission  intends  to  enter  into  consultations  with.  the  Member 
States  concerned  with  a  view  to  identifying  those  aspects  of  the 
national  systems  which  pose  the greatest  potential  problems  for  the 
internal market  and  the  manner  in  which  they  might  be  changed. -17-
4.  Coverage  by  the national  health  insurance  system 
It is  clear  that  Member  States  will  wish  to  retain  the  right  to 
exclude  entire  cat~gories of  medicinal  products  from  their  health 
insurance  system,  on  the grounds,  for  example,  that  such  products 
may  be  purchased  by  the  consumer  without  a  medical  prescription, or 
t~at the  products  are  intended  for  the symptomatic  relief of  minor 
and  self-limiting ailments. 
The  application  of  price  criteria  in  deciding  whether  to  exclude 
individual  products  from  the  scope  6f  the  health  insurance  system 
gives  rise to difficulties resulting from  the  interpretation of  the 
notion  of  therapeutic  equivalenre.  Within  the  framework  of 
medicines  licensing  (marketing  authorization>,  the  concept  of 
therapeutic  equivalence  has  a  relatively  clear  meaning:  the  same 
pharmaceutical  form  and  route  of  administration· together  with 
bio-equivalence.  However  if  this  approach  is  applied  to 
reimbursement,  it  means  that  the  vast  •ajority  of  medicinal 
products  are  automatically  eligible  for  reimbursement  unless  a 
generic  or  branded  gene~ic.copy is available.  For  this  reason,  in 
the framewotk  of  reimbursement,  the authorities  take a  wider  view 
of  equivalence,  looking  at  the ability  of  the  medicine  to  treat a 
particul~r disease at  a  given  cost  (cost/benefit  ev~luation).  Such 
an  approach  inevitably gives  rise to difficulties of  interpretation 
and  evaluation. 
It  therefore  appears  necessary  to  try  to  achieve  a  greater  degree 
of  coordination of  nation~l decisions.  In  the first  instance,  it 
may  be  desirable to consider  the establishment  of  a  Community  level 
\  . 
forum  in which  the  therapeutic  advantages  of  new  medicinal  products 
could  be  discussed,  having  regard  to  their  indications, 
contra~indications,  side  effects,  etc.  The  national  health 
authorities would  then  be  able to use  an  opinion  from  this forum  as 
the  basis  for  determining  the  status  of  a  product  within  the 
national  health  insurance system. ld' 
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PROPOSAL  FOR  A COUNCIL  DIRECTIVE 
RELATING  TO  THE  TRANSPARENCY  OF  MEASURES  REGULATING 
THE  PRICING  OF  MEDICINAL  PRODUCTS  FOR  HUMAN  USE 
AND  THEIR  INCLUSION  WITHIN  THE  SCOPE  OF  THE 
NATIONAL  HEALTH  INSURANCE  SYSTEM 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard to  tne  Treaty establisning the European  Economic  Community, 
and  in particular Article 100  thereof, 
Having  regard to the proposal  from  the  Commission·•, 
? 
Having  regard to  the opinion of  the  European  Parliament-i 
Having  regard to the opinion of  tne  Economic  and  Social  Committee3, 
Whereas  marketing  authorizations  for  proprietary  medicinal  products  issued 
pursuant  to  Council  Directive  65/65/EEC  of  26  January  1965  on  the 
approximation of provisions  laid down  by  law,  regulation or  administrative 
action relating  to proprietary  medicinal  ~roducts
4  may  be  refused only  for 
reasons  relating  to  the  quality,  safety  or  efficacy  of  the  proprietary 
medicinal  product  concerned; 
1 
2 
3 
4  OJ  No.  22  of  9.2.1965,  p.  369/65 -20· 
Whereas  Member  States  have  adopted  measures  of  an  economic  nature  on  the 
marketing  of  medicinal  products  in order to control or  reduce  public  health 
expenditures  on  medicinal  products;  whereas  such  measures  include  direct 
and  indirect  controls  on  the  prices  of  medicinal  products  and  Limitations 
on  the  range  of products  covered  by  the national  health  insurance  system; 
Whereas  the  primary  objective  of  such  measures  is  the  promotion  of public 
health  by  ensuring  the  availability  of  adequate  supplies  of  medicinal 
products  at  a  reasonable  cost; whereas  however  such  measures  should also be 
intended to  promote  efficiency  in the  production of  medicinal  products  and 
to encourage  research  and  development  into new  medicinal  ~roducts, on  which 
the  maintenance  of  a  high  level  of  public  health  within  the  Community 
ultimately depends; 
Whereas  disparities  in such  measures  may  hinder or  distort  intra-Community 
trade  in  medicinal  products  and  thereby  directly affect  the  functioning  of 
the  common  market  in medicinal  products; 
Whereas  as  a  first  step  towards  the  removal  of  these  disparities,  it  is 
urgently necessary  to  lay  down  a  series of  requirements  intended  to ensure 
that all  concerned  can  verify that  the national  measures  do  not  constitute 
quantitative  restrictions  on  imports  or  exports  or  measures  having 
equivalent  effect  thereto;  whereas,  however,  these  requirements  do  not 
effect  the  policies  of  the  Member  States  who  rely  primarily  upon  free 
competition to determine  the price of medicinal  products; 
Whereas  the  further  approximation  of  such  measures  must  take  place 
progressively; 
HAS  ADOPTED  THE  FOLLOWING  DIRECTIVE: -11-
Article 1 
1.  Member  States  shall  ensure  that  any  national  measure,  whether  Laid  down 
by  law,  regulation or  administrative action,  · to control  the prices of 
medicinal  products  for  human  use  or  to restrict  the  range  of  medicinal 
products  CO\fered  by  their  national  health  insurance  systems  complies 
~ith the  requirement~ of this Directive. 
2.  ihe  definition  of  "medicinal. products"  Laid  down  in  Article  1  of 
Council  Oi rective  65/65/EEC  of  26  January  1965  shall  apply  to  this 
Direr.tive. 
3.  Nothing  in  this  Directive  shall  permit  the  marketing  of  a  proprietary 
medicinal  product  in  respect  of  which  the authorization provided  f~r  in 
Article  3  of  Council  Directive  65/65/EEC  of  26  January  1965  has  not 
been  issued. 
ArticlP.  2 
The  follo~ing  provisions  shall  apply  if  the  marketing  of  a  medicinal 
product  is  permit ted  only  after  the  competent  authorities  of  the  Member 
State  concerned  have  approved  the price of  the product: 
1.  Member  States  shall  ensure  that  a  decision  on  the  price  which  may  be 
charged  for  the  medicinal  product  concerned 
to  the  applicant  within  90  days  of  the 
submitted  in  due  form.  In  the  absence 
is  ad6pted  and  communicated 
receipt  of  an  application 
of  such  a  decision,  the 
applicant  shall  be  entitled  to  market  the  product  at  the  price 
proposed. 2.  Should  the  competent  authorities decide  not  to  permit  the  marketing of 
the medicinal  product  concerned  at  the price proposed  by  the applicant, 
the  decision  shall  contain  a  detailed  statement  of  reasons.  In 
addition,  the  applicant  shall  be  informed  of  the  remedies  available to 
him  under  the  laws  in  force  and  the  time-limits  allowed  for  applying 
for  such  remedies. 
3.  At  least  once  every  six  months  the competent  authorities shall  publish 
in  an  appropriate  official  publication  and  communicate  to  the 
Commission  a  list of  the medicinal  products  whose  price  has  been  fixed 
during  the  relevant . period  together  with  the  prices  which  may  be 
charged  for  such  products. 
Article 3 
Without  prejudice  to Article 4,  the  following  provisions shall apply  if an 
increase  in  the price  of  a  medicinal  product  is permitted  only after prior 
approval  has  been  obtained from  the  competent  authorities: 
1.  Member  States  shall  ensure  that  a  decision  is adopted  on  an  application 
submitted  in  due  form  to  increase  the price  of  a  medicinal  product  and 
communicated  to  the  applicant  within  90  days  of  its  receipt.  In  the 
absence  of  such  a  decision,  the  applicant  shall  be  entitled to apply  in 
full  the price  increase  requested. 
2.  Should  the  competent  authorities decide  not  to permit  the whole  or part 
of  the price  increase  requested,  the decision shall  contain a  detailed 
statement  of  reasons  and  the  applicant  shall  be  informed  of  the 
remedies  available  to  him  under  the  laws  in  force  and  the  time-limits 
allowed  for  applying  for  such  remedies. 3.  At  least  once  every  six  months  the  competent  authorities  shall  publish 
in  an  approp~iate  official  publication  and  communicate  to  the 
Commission  a  list of  the  medicinal  products  for  which  price  increases 
have  been  granted  during  the  relevant  period  together  with  the  new 
price which  may  be  charged  for  such  products. 
Article 4 
1.  In  the  event  of a  freeze  being  imposed  on  the  prices of  all medicinal 
products  or  certain  categories  of  medicinal  products,  Member  States 
shall.ensure that  prices are  reviewed,  and  where  appropriate adjusted, 
at  least  once  a  year  or  when  the  national  resale  price· index  has 
increased  by  ten  per  cent  since  the  last  review,  whichever  is  the 
sooner.  Within  90  days  of  the  commencement  of  this  review  the 
competent  authorities  shall  announce  what  increases  or  cler;reases  in 
prices are being made. 
2.  Any  person  who  is  responsible  for  marketing  a  medicinal  product  may 
apply  for  a  derogation  from. a  price  freeze,  stating  his  reasons  in 
detail.  Member  States  shall  ensure  that  a  reasoned  decision  on  any 
such  application  is adopted  and  communicated  to the applicant  within  90 
days.  In  the  absence  of  such  a  decision,  the  app l i cC!Int  shall  be 
entitled  to  apply  in  full  the  price  increase  requested.  Should  the 
derogation  be  granted,  the  competent  authorities  shall  forthwith 
publish  an  announcement  of  the price  increase allowed. 
Article 5 
Where  a  Member  State  adopts  a  system  of  direct  or  indirect  controls on  the 
profitability  of  manufacturers  and  importers  of  medicinal  products,  tile 
Member  State  concerned  shall  publish  the  following  information  in  an 
appropriate official publication and  communicate  it to the  Commission: -"14-
a>  the  method  or  methods  used  to  define  profitability;  return  on  sales 
and/or  return on  capital, 
b)  the  criteria  according  to  which  target  rates of  profit are  accorded  to 
individual  manufacturers  or  importers  together  with  the  criteria 
according  to which  manufacturers or importers will  be  allowed  to  retain 
profits above  their given  targets, 
c>  the  range  of target profit,  including the  average  target  rate of profit 
for  manufacturers  or  importers  for  the  previous  year  and  the  current 
year, 
d)  whether  any  company  failed  to  reach  their allocated target, 
e)  the  maximum  percentage  profit  which  any  manufacturer  or  importer  has 
been  allowed  to  retain above  their target. 
This  information  shall  be  updated  at  least once  a  year. 
Where,  in addition  to  a  system  of direct or  indirect  controls on  profits, a 
Member  State  operates  a  system .of  controls  on  the  prices  of  certain  types 
of  medicinal  products,  which  are  excluded  from  the  scope  of  the  profit 
control  scheme,  the provisions of  Articles  2 - 4  shall apply  to  such  price 
controls.  However,  Articles  2  - 4  shall  not  apply  where  the  normal 
operation  of  a  system  of  direct  or  indirect  controls  on  profits  results 
exceptionally  in  a  price  being  fixed for  an  individual  medicinal  product. 
Article 6 
The  following  provisions  shall  apply  if  a  medicinal  product  is  covered  by 
the  national  health  insurance  system  only  after  the  competent  authorities 
have  decided  to  include  the  medicinal  product  concerned  in a  positive list 
of  medicinal  products  covered  by  the national  health  insurance  system. -tS· 
1.  Member  States  shall ensure  that  a  decision on  an  application  submitted 
in  due  form  to· include  a  medicinal  product  in  the  list  of  medicinal 
products  covered  by  the  health  insurance  system  is  adopted  and 
communicated  to  the  applicant  within  90  days  of  its  receipt.  An 
application · under  this  Article  may  be  made  before  the  competent 
authorities  have  agreed  the  price  to  be  charged  for  the  product 
pursuant  to  Articl~ 2. 
2.  Any  decision not  to  include a  medicinal  product  in  the  list of  products 
covered  by  the  health  insurance  system  shall  state  in  detail  the 
reasons  upon  which  it  is  based.  In  addition  the  applicant  shall  be 
informed  of  the  remedies  available to him  under  the  laws  in force,  and 
the time-limits allowed  for  applying  for  such  remedies. 
3.  Before  the  date  referred  to  in  Article  11<1)  of  this  Directive  the 
Member  States  shall  publish  in  an  appropri~te official  publication and 
communicate  to  the  Commission  the  criteria  which  are  to  be  taken  into 
account  by  the  competent  authorities  in  deciding  whether  or  not  to 
include medicinal  products on  the  lists. 
4.  Within  one  year  of  the  date  referred  to  in  Article  11<1)  of  this 
Directive,  the  Member  States  shall  publish  in an  appropriate official 
publication  and  communicate  to  the  Commission  a  complete  list  of  the 
products covered  by  their health  insurance system,  together with  their 
prices. 
months. 
This  information  shall  be  updated  at  least  once  every  six Article 7 
The  following  provisions  shall  apply  if. the  competent  authorities  of  a 
Member  State  are  empowered  to  adopt  decisions  to  exclude  individual  or 
categories  of  medicinal  products  from  the  coverage  of  its  national  health 
insurance system  (negative  lists>. 
1.  Any  decision  to  exclude  a  category  of  medicinal  products  from  the 
coverage  of  the  national  health  insurance  system  shall  state  in detail 
the  reasons  on  which  it  is  based  and  be  published  in  an  appropriate 
official publication. 
2.  Before  the date  referred to in  Article 11(1)  of this Directive,  Member 
States  shall  publish  in  an  appropriate  official  publication  and 
communicate  to  the  Commission  the  criteria  which  are  to  be  taken  into 
account  by  the  competent  authorities  in  deciding  whether  or  not  to 
exclude  an  individual  medicinal  product  from  the  coverage  of  the 
national  health  insurance system. 
3.  Any  decision  to  exclude  an  individual  medicinal  product  from  the 
coverage  of  the  national  health  insurance  system  shall  state  in detail 
the  reasons  on  which  it is  based.  Such  decisions  shall be  communicated 
to  the  person· responsible,  who  shall  be  informed  of  the  remedies 
available  to  him  under  the  laws  in  force  and  the  time-limits  allowed 
for  applying  for  such  remedies. 
4.  Within  one  year  of  the  date  referred  to  in  Article  11 C1>  of  this 
Directive,  the  competent  authorities  shall  publish  in  an  appropriate 
official  publication  and  communicate  to  the  Commission  a  list  of  the 
individual  medicinal  products  which  have  been  excluded  from  the  scope 
of  its  health  insurance  system.  This  information  shall  be  updated  at 
least  every  six  months. Article 8 
1.  Before  the  date  referred  to  in  Article  11<1)  of  this  Directive,  the 
Member  States  shall  communicate  to  the  Commission  any  therapeutic 
classification  of  medicinal  products  which  is  used  by  the  competent 
authorities  for  the  purposes  of  the  national  social  security  system. 
If it considers it necessary,  the  Commission  may,  after considering the 
opinion of  the  Committee  referred to  in Article  10,  adopt  a  directive 
on  the  approximation  of  national  provisions  relating  to  the 
classification of  medicinal  products  for  social security purposes. 
2.  Before  the  date  referred  to  in  Article  11<1)  of  this  Directive,  the 
Member  States  shall  communicate  to  the  Commission  the  criteria  which 
are  used  by  the  competent  authorities  in verifying  the  fairness  of  the 
prices  charged  for  transfers  within  a  group  of  companies  of  active 
principles  or  intermediate  products  used  in  the  manufacture  of 
medicinal  products.  If it  considers  it necessary,  the  Commission  may, 
after  considering  the  opinion  of  the  Committee  referred  to  in 
Article 10,  adopt  a  directive or  issue guidelines  on  the  approximation 
of  national  criteria  for  the  verification  of  the  fairness  of  such 
prices. 
Article 9 
1.  In  the  light  of  experience,  the  Commission  shall,  not  later  than  two 
years  after  the  date  referred  to  in  Article  11(1)  of  this  Directive, 
~ubmit  to  the  Council  ~  proposal  cohtaining  appropriate  measures 
leading  towards  the  abolition  of  any  remaining  barriers  to  or 
distortions of  the  free  movement  of  proprietary medicinal  products. 
2.  The  Council  shall decide  on  the  Commission  proposal not  later  than  one 
year after its submission. Article 10 
1.  A Committee  called the  Consultative  Committee  on  Pharmaceutical  Pricing 
and  Reimbursement  shall be  set  up  and  attached to the  Commission. 
2.  The  tasks of  the  Committee  shall  be: 
-to examine  any  question  relating to the  application of  this Directive 
which  is  brought  up  by  its  chairman  either  on  his  initiative or  at 
the  request  of  a  Member  State; 
to  discuss  and  provide  an  opinion  on  matters  referred  to  it  by  the 
Commission  pursuant  to  Article  8  of  this  Directive  or  in  accordance 
with  the  provisions  of  any  future  directive.  When  seeking  the 
opinion of  the  Committee,  the  Commission  may  set  a  time-limit  within 
which  such  an  opinion  shall  be  given.  No  vote  shall  be  taken. 
However  any  member  of  the  Committee  may  demand  that  his  views  be  set 
down  in  the  minutes. 
3.  The  Committee  shall  consist  of  one  representative  from  each  Member 
State.  There  shall  be  one  deputy  for  each  representative.  This  deputy 
shall  be  entitled to participate in meetings  of  the  Committee. 
4.  A representative of  the  Commission  shall  chair the  Committee. 
5.  The  Committee  shall adopt  its rules of  procedure. .. • 
-~-
Article 11 
1.  Member  States  shall  bring  into  force  the  laws,  regulations  and 
administrative  provisions  necessary  to  comply  with  this  Directive  by 
1  January  1989  at  the  latest.  They  shall  forthwith  inform  the 
Commission  thereof. 
2.  Before  the  date  referred  to  in  paragraph  1,  Member  States  shall 
communicate  to  the  Commission  the  texts  of  any  law  ··regulations  or 
administrative  provisions  relating  to  the  pricing  of  medicinal 
products,  the profitability of manufacturers of  medicinal  products  and 
the  .coverage  of  medicinal  products  by  the  national  health  insurance 
system.  Amendments  and  modifications  to  these  laws,  re_gulations  or 
administrative  provisions  shall  be  communicated  to  the  Commission 
forthwith. 
Article 12 
This  Directive is addressed to the  Member  States. FINANCIAL  STATEMENT 
relating to the  Commission  proposal  for  a  Council  Directive 
relating to  the  transparency of  measures  regulating  the pricing of 
medicinal  products  for  human  use  and  their  inclusion within 
the  scope  of  the national  health  iMsurance  system 
Although  the measures  proposed  do  not  strictly constitute new  actions,  they 
will  result  in  new  responsibilities  for  the  Commission  department  concerned 
COG  III/A/3 "Pharmacy  and  Veterinary Medicines"). 
1.  Budget  headings 
No  1100  salaries of  officials and  temporary  agents 
No  2510  travelling  expenses  of  members  of  institutionalised committees 
No  2600  expenses  of  studies,  experts  and  consultants 
N°  1301  missions 
2.  Legal  basis 
Article 100  (100  A)  of  the  EEC  Treaty 
3.  Description of  the  project 
- to ensure  that  national  systems  to  limit  public  health  expenditures 
on  medicinal  products  do  not  disrupt  the operation of  the  internal 
market 
a)  to  study  the detailed effects of  national  price  control  and  reimbursement 
systems  on  the operation of  the  common  market  and  make  detailed pr9posals 
for  appropriate adjustment; 
b)  to  coordinate  certain aspects  of  the operation of national  price  control 
and  reimbursement  systems  in particular the  classification of medicines 
for  reimbursement  purposes  and  the  assessment  of  the  reasonableness  of 
transfer prices; 
c)  to assess  the  impact  of divergencies  in price  control  and  reimbursement 
systems  on  industrial efficiency and  innovation within the framework 
of  the  Commission's  programme  of  research  into the"cost of  non-Europ~'. 
4.  Justification of  the  project 
There  are wide  disparities between  national  systems  of  price control  and 
reimbursement  of  medicinal  products  within the  Community.  These  differences 
result  from  fundamental  differences  in political and  economic  philosophy 
and  it is not  realistically feasible  to undertake  the full-scale approximation 
of  national  price  control  systems  at present.  The  resources  presently 
available to  the  Commission  service  responsible are  not  adequate to undertake 
the detailed studies  and  negotiations  with  Member  States which  are  required  • 
• I • • ·' 
•• 
The  ope~ation of  ~ational  syste~s of price  control  and  soci~l security 
reimbursament  c.re  resulti:1q  ir.  major  disparities  in  the price of 
p~armaceuticals, which  are  resulting  iM  distortions of  intra-Community 
trade,  and  are being  criticised  by_t~e European  Parlial!lent,  the  Industry 
and  consumer  groupsw 
5.  Financial  implic~t1ons for  personnel  and  operating appropriations 
a)  Ac!1itional  personnel  for  DG  III/A/3 "Pharmacy  .;nd  Veterinary Medicines" 
frrirn  1988: 
~  economist  with  knowledge  of  the problems  of  price formation  in 
t~e pharmaceutical  sector'CA7> 
- 1  secretary  CC3l 
b)  Allowance  for  meetings  of  institutional  committees  from  1988: 
- 4  me~tings of  national  experts  en  price  control  p~r annum 
~travelling expenses  for  2  experts  per  Member  State -! 40.000  ECU/p.a.) 
c)  Appropriations  for outside consultants, multi-client  studies  and 
economic  documentation  on  pharmaceutical pricing and  reimbursement 
(+  100.000  ECU/p.a.) 
d)  Appropriations  for  missions  to the  competent  national authorities STATEMENT  OF  IMPACT  ON  SMALL  AND  MEDIUM-SIZED  FIRMS 
AND  EMPlOYMENT 
1.  ADMINISTRATIVE  OBLIGATIONS  ARISING  FROM  THE  APPLICA.TION  OF  THE 
LEGISLATION  FOR  FIRMS 
The  proposal will  not  increase the obligations on  firms  which  result 
from  national  price control procedures. 
2.  ADVANTAGES  FOR  THE  FIRM 
- YES/Nil 
- WHICH  - greater transparency  in national decision-making  procedures 
relating to price control  and  reimbursement  of medicines 
3.  INCONVENIENCE  FOR  THE  FIRM 
XIS/NO 
CONSEQUENCES 
4.  EFFECT  ON  EMPLOYMENT 
No  direct effects. 
5.  HAS  PRIOR  CONCERTATION  WITH  THE  SOCIAL  PARTNERS  TAKEN  PLACE? 
YES/KII  - consultation of  pharmaceutical  industry 
OPINION  OF  SOCIAL  PARTNERS  - generally  favourable 
6.  IS  THERE  A LESS  RESTRICTIVE  ALTERNATIVE? 
No. 
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